These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22778174)

  • 1. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
    Erdmann E; Semigran MJ; Nieminen MS; Gheorghiade M; Agrawal R; Mitrovic V; Mebazaa A
    Eur Heart J; 2013 Jan; 34(1):57-67. PubMed ID: 22778174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
    Gheorghiade M; Greene SJ; Filippatos G; Erdmann E; Ferrari R; Levy PD; Maggioni A; Nowack C; Mebazaa A;
    Eur J Heart Fail; 2012 Sep; 14(9):1056-66. PubMed ID: 22713287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H; Mitrovic V; Franz N; Heuer H; Buerke M; Wolfertz J; Mueck W; Unger S; Wensing G; Frey R
    Circulation; 2009 Jun; 119(21):2781-8. PubMed ID: 19451356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
    Mueck W; Frey R
    Clin Pharmacokinet; 2010; 49(2):119-29. PubMed ID: 20067336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
    Sawabe T; Chiba T; Kobayashi A; Nagasaka K; Aihara K; Takaya A
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00463. PubMed ID: 30873284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
    Frey R; Mück W; Unger S; Artmeier-Brandt U; Weimann G; Wensing G
    J Clin Pharmacol; 2008 Dec; 48(12):1400-10. PubMed ID: 18779378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
    Tamargo J; Duarte J; Caballero R; Delpón E
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1039-47. PubMed ID: 20730699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic and clinical effects of ularitide in decompensated heart failure.
    Mitrovic V; Seferovic PM; Simeunovic D; Ristic AD; Miric M; Moiseyev VS; Kobalava Z; Nitsche K; Forssmann WG; Lüss H; Meyer M
    Eur Heart J; 2006 Dec; 27(23):2823-32. PubMed ID: 17074775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
    Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
    N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.
    Lettieri JT; Scheerans C; Blunck M; Mazzu AL; Frey R; Mück W; Sundaresan PR
    J Clin Pharmacol; 2012 Aug; 52(8):1240-7. PubMed ID: 21868716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
    Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
    Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Tita C; Gilbert EM; Van Bakel AB; Grzybowski J; Haas GJ; Jarrah M; Dunlap SH; Gottlieb SS; Klapholz M; Patel PC; Pfister R; Seidler T; Shah KB; Zieliński T; Venuti RP; Cowart D; Foo SY; Vishnevsky A; Mitrovic V
    Eur J Heart Fail; 2017 Oct; 19(10):1321-1332. PubMed ID: 28677877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat.
    Dautzenberg M; Kahnert A; Stasch JP; Just A
    Am J Physiol Renal Physiol; 2014 Nov; 307(9):F1003-12. PubMed ID: 25209860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
    Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
    Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
    Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
    Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.